In Brief: La Jolla Diagnostics
This article was originally published in The Gray Sheet
Executive Summary
La Jolla Diagnostics: Announces "close-out" sale of its inventory of antisera (various reagents containing antibodies that counter immunoglobulins) to focus on other products. A breast cancer diagnostic test using DNA fingerprinting technology and a heart attack predictor are currently in development, as is an ophthalmic and nasal spray product line. The close-out should bring in "significant revenue" in the next three years, the La Jolla, California company predicts...